18F‐FDG‐PET and 18F‐FDG‐PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta‐analysis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medical Imaging and Radiation Oncology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1754-9485.2012.02344.xPMID 22498184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer

  2010cited by this paper
• Endocrine tumors: The evolving role of positron emission tomography in diagnosis and management

  2010cited by this paper
• Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.

  2010cited by this paper
• Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

  2010cited by this paper
• Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma

  2009cited by this paper
• Medullary thyroid cancer: early detection and novel treatments

  2009cited by this paper
• The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.

  2008cited by this paper
• Functional nuclear medicine imaging of medullary thyroid cancer

  2008cited by this paper
• Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.

  2008cited by this paper
• 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation

  2008cited by this paper
• Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

  2007cited by this paper
• Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT

  2007cited by this paper
• Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.

  2007cited by this paper
• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• Medullary thyroid cancer: monitoring and therapy.

  2007cited by this paper
• Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

  2007cited by this paper
• High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer.

  2005cited by this paper
• 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature

  2004cited by this paper
• Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer

  2004cited by this paper
• Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.

  2004cited by this paper
• 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

  2002cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study

  2001cited by this paper
• Current approaches and perspectives in the therapy of medullary thyroid carcinoma

  2001cited by this paper
• Medullary thyroid carcinoma

  2000cited by this paper
• The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.

  2000cited by this paper
• Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging.

  1999cited by this paper
• Medullary carcinoma of the thyroid: current diagnosis and management.

  1991cited by this paper
• Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.

  1991cited by this paper

• Medullary Thyroid Carcinoma: Imaging.

  2025cites this paper
• CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma

  2024cites this paper
• Diagnostic tests for medullary thyroid carcinoma: an umbrella review

  2023cites this paper
• Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities

  2023cites this paper
• Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.

  2023cites this paper
• PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

  2021influential citation
• Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies.

  2021cites this paper
• Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

  2021cites this paper
• Usefulness of PET-CT scan in recurrent thyroid cancer

  2020cites this paper
• Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma

  2020cites this paper
• Evidence-Based PET for Endocrine Tumours and Disorders

  2020cites this paper
• F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients

  2019cites this paper
• FEP Medical Policy Manual FEP 6.01.26 Oncologic Applications of Positron Emission Tomography Scanning

  2019cites this paper
• Medullary Thyroid Carcinoma

  2018cites this paper
• Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

  2017cites this paper
• Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

  2017cites this paper
• Systematic reviews of diagnostic tests in endocrinology: an audit of methods, reporting, and performance

  2017cites this paper
• SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

  2017cites this paper
• Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

  2016cites this paper
• Medullary Thyroid Carcinoma: Imaging.

  2015cites this paper
• Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.

  2015cites this paper
• Medullary Thyroid Cancer

  2015cites this paper
• [Importance of PET for surgery of recurrent thyroid cancer].

  2014cites this paper
• PET/CT imaging of neuroendocrine tumors with 68Gallium-labeled somatostatin analogues: An overview and single institutional experience from India

  2014cites this paper
• Bedeutung der PET für die Chirurgie des Schilddrüsenkarzinomrezidivs

  2014cites this paper
• Advances in management of thyroid cancer.

  2013cites this paper
• What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

  2013cites this paper
• 18F‐FDG and new positron emitter radiotracers for detecting recurrent medullary thyroid carcinoma

  2012cites this paper